X

NSCLC

NSCLC

Stage IV PD-L1–High Non–Small Cell Lung Cancer: Immunotherapy Alone or With Chemotherapy?

Except in patients with no smoking history, the addition of CT to immunotherapy does not add benefit as a first-line treatment in patients with stage IV nonsquamous NSCLC and high expression of PD-

The ASCO Post
05/12/2021
Neoadjuvant Nivolumab Plus Chemotherapy Boosts Pathologic Complete Response in Resectable NSCLC

Neoadjuvant CT with nivolumab plus platinum-doublet chemotherapy significantly improves pathologic complete response rates compared with CT alone in patients with resectable stage IB to IIIA NSCLC.

The ASCO Post
05/10/2021
VTE Incidence in NSCLC Varies by Treatment Type

Venous thromboembolism rates among patients with advanced non-small cell lung cancer varied by treatment type, according to retrospective study results.

Healio
05/09/2021

Superior Survival With Sintilimab in Squamous NSCLC

Second-line treatment with sintilimab improves survival, when compared with docetaxel, in patients with advanced/metastatic squamous non–small cell lung cancer in a phase 3 trial.

Medscape
05/04/2021
GEO Data Mining Identifies OLR1 as a Potential Biomarker in NSCLC Immunotherapy

In this study, investigators attempt to explore TME and identify a potential biomarker for NSCLC immunotherapy.

Frontiers in Oncology
04/20/2021
First-Line Immune Checkpoint Inhibitor Monotherapy vs Chemoimmunotherapy in Advanced NSCLC According to KRAS Variant Status

Sun et al find that first-line immune checkpoint inhibitor monotherapy is associated with better OS among patients with advanced NSCLC with PD-L1 expression ≥ 50% and KRAS variant vs KRAS wild-type

The ASCO Post
05/03/2021
First-Line Nivolumab/Ipilimumab Plus Chemotherapy Improves Overall Survival vs Chemotherapy in Stage IV or Recurrent NSCLC

This phase III trial has shown improved OS with first-line nivolumab/ipilimumab plus two cycles of CT vs four cycles of CT alone in patients with stage IV or recurrent NSCLC without EGFR o

The ASCO Post
04/25/2021
Presurgical Nivo/Chemo Boosts pCR Rates in NSCLC

 

Results from the CheckMate 816 trial show that pCR rates improved from 2.2% with chemotherapy alone to 24% when nivolumab was added.

Medscape
04/12/2021
Neoadjuvant Nivolumab Plus Chemotherapy Boosts Pathologic Complete Response Rate for Patients With Resectable NSCLC

Neoadjuvant nivolumab plus platinum-doublet chemotherapy significantly improves pCR rates compared with chemotherapy alone in patients with resectable stage IB to IIIA NSCLC.

The ASCO Post
04/12/2021
Synergistic Effects of Type I PRMT and PARP Inhibitors Against Non–Small-Cell Lung Cancer Cells

Given that epigenetic modulators such as protein arginine methyltransferases are frequently overexpressed in cancers, PRMT inhibitors are a promising class of cancer therapeutics.

Clinical Epigenetics
03/10/2021
Final Results From the International Tailored Chemotherapy Adjuvant Trial

Findings from a Phase III study found that evaluating mRNA expression of selected genes to tailor adjuvant chemotherapy did not improve survival outcomes among patients with resected stage II-III N

Oncology Times - Latest Articles
04/01/2021
Next Up in NSCLC: Antibody-Drug Conjugates

Antibody-drug conjugates directed against HER2, HER3, and trophoblast cell-surface antigen 2 are showing encouraging antitumor activity in advanced non–small cell lung cancer.

The ASCO Post
03/25/2021
Significant Variation Found in Timing & Selection of Genetic Tests for NSCLC

Biomarker testing surveys specific disease-associated molecules to predict treatment response and disease progression; however, its use has complicated the diagnosis of non-small cell lung cancer.<

Oncology Times - Latest Articles
03/22/2021
Ipilimumab + Pembrolizumab Shows No Benefit for Patients With NSCLC

The addition of ipilimumab to pembrolizumab does not improve efficacy among metastatic NSCLC patients with high levels of PD-L1 expression, according to Phase III findings presented...

Oncology Times - Latest Articles
03/15/2021
Statistical and Bioinformatic Analysis of Hemimethylation Patterns in Non–Small-Cell Lung Cancer

This research focuses on studying non-small cell lung cancer hemimethylation, which refers to methylation occurring on only one of the two DNA strands.

BMC Cancer
03/12/2021
A Highly Expressed mRNA Signature for Predicting Survival in Patients With Stage I/II Non–Small-Cell Lung Cancer After Operation

This study explores mRNA signature closely related to the prognosis of NSCLC by new algorithm of bioinformatics.

Scientific Reports
03/12/2021
Estimating Survival in Patients with Non-Small-Cell Lung Cancer and Brain Metastases: A Verification of the Graded Prognostic Assessment for Lung Cancer Using Molecular Markers

This study aims to validate the feasibility of the Lung-molGPA in NSCLC.

OncoTargets and Therapy
03/02/2021
Tumor Suppressor miR-584-5p Inhibits Migration and Invasion in Smoking Related Non-Small Cell Lung Cancer Cells by Targeting YKT6

Study investigators find that miR-584-5p expression is downregulated with cancer progression using a lung carcinogenesis model cell line.

Cancers
03/08/2021
Novel Emerging Molecular Targets in Non-Small Cell Lung Cancer

This review covers the molecular alterations with a potential clinical impact in NSCLC, including amplifications or mutations of the MET factor, fusions of RET, rearrangements of the NTRK genes...<

International Journal of Molecular Sciences
03/05/2021
Pembrolizumab Plus Ipilimumab or Placebo for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%

Pembrolizumab monotherapy is standard first-line therapy for metastatic NSCLC with programmed death ligand 1 tumor proportion score ≥ 50% without actionable driver mutations.

Journal of Clinical Oncology
Lung Stereotactic Body Radiation Therapy for Elderly Patients Aged ≥ 80 Years With Pathologically Proven Early-Stage Non-Small Cell Lung Cancer

This study aims to assess the clinical utility of SBRT for elderly patients aged ≥ 80 years with pathologically proven early-stage NSCLC.

Radiation Oncology
02/23/2021
High Lymphocyte Population-Related Predictive Factors for a Long-Term Response in Non-Small Cell Lung Cancer Patients Treated With Pemetrexed

This study investigates the clinical characteristics and predictive factors in patients with advanced NSq-NSCLC who underwent long-term PEM maintenance therapy.

Journal of Translational Medicine
02/28/2021
Clinical Outcomes and Prognostic Factors of Salvage Stereotactic Body Radiotherapy for Post-Surgical Thoracic Oligo-Recurrence/Metastasis of Non-Small-Cell Lung Cancer

The study assesses the efficacy and safety of SBRT using CyberKnife in patients with postoperative thoracic oligo-recurrence/metastasis of NSCLC, and to analyze the...

Cancer Management and Research
02/23/2021
Synergistic Roles of Curcumin in Sensitising the Cisplatin Effect on a Cancer Stem Cell-Like Population Derived from Non-Small Cell Lung Cancer Cell Lines

This study shows the efficacy of curcumin as a chemo-sensitiser in CSCs subpopulation of NSCLC using the lung cancer adenocarcinoma human alveolar basal epithelial cells A549 and H2170.

Molecules
02/18/2021
ZNF674-AS1 Antagonizes miR-423-3p to Induce G0/G1 Cell Cycle Arrest in Non-Small Cell Lung Cancer Cells

This work investigates the expression of ZNF674-AS1 in 83 pairs of NSCLC specimens and adjacent noncancerous lung tissues.

02/22/2021
Clinicopathological Significance and Prognostic Value of E-Cadherin Expression in Non-Small Cell Lung Cancer

The purpose of the study is to explore the clinicopathological features and prognostic value of E-cadherin expression in non-small cell lung cancer by meta-analysis.

Medicine
02/19/2021
The Role of Long Intergenic Non-Coding RNA for Kinase Activation (LINK-A) as an Oncogene in Non-Small Cell Lung Carcinoma

The present study aims to evaluate the impact of down-regulation of LINK-A in A549 and Calu-3 cell lines as cellular models of non-small cell lung carcinoma.

Scientific Reports
02/18/2021
Use Tumor Suppressor Genes as Biomarkers for Diagnosis of Non-Small Cell Lung Cancer

To find high efficient biomarkers for clinical diagnosis of NSCLC patients, this study uses gene differential expression and gene ontology to define a set of 26 tumor suppressor genes.

Scientific Reports
02/12/2021
The Surgical Perspective in Neoadjuvant Immunotherapy for Resectable Non-Small Cell Lung Cancer

The recent novel conception of neoadjuvant immunotherapy has generated interest among surgeons worldwide, especially the lack of experience involving surgical treatment...

01/29/2021
Development and Characterization of Patient-Derived Xenografts From Non-Small Cell Lung Cancer Brain Metastases

This study reports on a direct-from patient-derived xenograft model system of NSCLC brain metastases with genomic annotation useful for translational and mechanistic studies. 

Scientific Reports
01/28/2021
The Improbable Targeted Therapy: KRAS as an Emerging Target in Non-Small Cell Lung Cancer

This study reviews promising therapeutics tested for KRAS mutant NSCLC.

01/19/2021
High LARGE1 Expression May Predict Benefit from Adjuvant Chemotherapy in Resected Non-Small-Cell Lung Cancer

The data were collected from the TCGA database to investigate LARGE1 expression in stage I–III NSCLC and explore its associations with clinicopathological parameters and OS of patients.

01/18/2021
Long-Term Survival of Patients with Metastatic Non-Small-Cell Lung Cancer over Five Decades

Major advances over the past five decades include the introduction of combination CT, small molecules targeting mutant proteins, especially EGFR, and more recently immunotherapy.

01/12/2021
The Average Copy Number Variation of Chromosome Fragments is a Potential Surrogate for Tumor Mutational Burden in Predicting Responses to Immunotherapy in Non‐Small‐Cell Lung Cancer

The tumor mutational burden is closely related to immunotherapy outcome. However, the cost of TMB detection is extremely high, which limits its use in clinical practice. 

01/04/2021
Second-Line Therapy Improves Overall Survival in Primary Refractory Non-Small Cell Lung Cancer Patients

This study investigates the outcome of all consecutive and unselected patients receiving palliative CT in a single institution to assess the efficacy of second-line CT in primary refractory NSCLC.<

01/07/2021
The Impact of Air Pollution Exposure on the MicroRNA Machinery and Lung Cancer Development

This review searches current literature for miRNAs involved in lung cancer, as well as miRNAs deregulated as a result of exposure to air pollutants.

01/19/2021
Prognostic Factors Determining Survival of Patients Operated for Non-Small Cell Lung Cancer with Consideration Given to Morphological Parameters of Blood

The aim of the study is to determine prognostic parameters which, in early diagnostics, best determine survival of patients, operated on due to NSCLC.

01/18/2021
Mimicking Tumor Hypoxia in Non-Small Cell Lung Cancer Employing Three-Dimensional In Vitro Models

This review defines current knowledge in the field of tumor hypoxia in NSCLC, including biology, biomarkers, in vitro and in vivo studies and also hypoxia imaging and detection.

Cells
01/12/2021
Treatment of Brain Metastases of Non-Small Cell Lung Carcinoma

Lung cancer is one of the most common malignant neoplasms. As a result of the disease’s progression, patients may develop metastases to the central nervous system.

International Journal of Molecular Sciences
01/08/2021
The Lymph Node Ratio Predicts Cancer-Specific Survival of Node-Positive Non-Small Cell Lung Cancer Patients

Lymph node ratio has been suggested to be an effective prognostic tool for stratifying non-small cell lung cancer cases.

01/19/2021
Intercellular Transfer of Exosomal Wild Type EGFR Triggers Osimertinib Resistance in Non-Small Cell Lung Cancer

EGFR-mutated lung cancer constitutes a major subgroup of NSCLC and osimertinib is administrated as first-line treatment.

01/18/2021
Stage-Specific PET Radiomic Prediction Model for the Histological Subtype Classification of Non-Small-Cell Lung Cancer

To investigate the impact of staging on differences in glucose metabolic heterogeneity between lung ADC and SCC by 18F-FDG PET textural analysis...

01/12/2021
The Role of Anti-Angiogenesis in the Treatment Landscape of Non-Small Cell Lung Cancer – New Combinational Approaches and Strategies of Neovessel Inhibition

This review summarizes the current knowledge of tumor-angiogenesis and corresponding anti-angiogenic therapies, as well as new aspects concerning characterization of tumor-associated vessels...

01/05/2021
RNA-Based Assay for Next-Generation Sequencing of Clinically Relevant Gene Fusions in Non-Small Cell Lung Cancer

Gene fusions represent novel predictive biomarkers for advanced NSCLC patients.

Cancers
01/04/2021
The Implications of Clinical Risk Factors, CAR Index, and Compositional Changes of Immune Cells on Hyperprogressive Disease in Non-Small Cell Lung Cancer Patients Receiving Immunotherapy

This study aims to investigate implications of clinical factors and immune cell composition on different tumor responses to immunotherapy in patients with NSCLC.

BMC Cancer
01/05/2021
MEK Inhibitors for the Treatment of Non-Small Cell Lung Cancer

Concomitant mutations in both KRAS and BRAF genes have been identified in non-small cell lung cancer.

01/05/2021
Functional Signatures in Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis of Sex-Based Differences in Transcriptomic Studies

This study aims to assess the molecular mechanisms underlying those differences through functional profiling and meta-analysis of lung adenocarcinoma expression datasets. 

Cancers
01/05/2021
Long Term Results of Single-Fraction Carbon-Ion Radiotherapy for Non-small Cell Lung Cancer

This study suggests that single-fraction passive carbon-ion radiotherapy can serve as an alternate treatment for patients with early-stage non-small cell lung cancer...

Cancers
12/31/2020
CHID1 Is a Novel Prognostic Marker of Non-Small Cell Lung Cancer

This study evaluates immune cells markers in 100 NSCLC specimens. Immunohistochemical analysis reveals no prognostic value for the markers studied, except CD163 and CD206.

International Journal of Molecular Sciences
01/05/2021
Multiple microarray analyses identify key genes associated with the development of Non-Small Cell Lung Cancer from Chronic Obstructive Pulmonary Disease

This study aims to analyze the key genes and potential molecular mechanisms that are involved in the development from COPD to NSCLC.

01/01/2021
Mutation Profile of Non-Small Cell Lung Cancer Revealed by Next Generation Sequencing

Precision therapy for lung cancer requires comprehensive genomic analyses.

01/06/2021
NUCKS1 Promotes Proliferation, Invasion and Migration of Non-Small Cell Lung Cancer by Upregulating CDK1 Expression

The aim of this study is to investigate the roles of nuclear casein kinase and cyclin-dependent kinase substrate 1 in NSCLC and to identify the potential mechanisms.

12/24/2020
Dyspnea in Patients Receiving Radical Radiotherapy for Non-Small Cell Lung Cancer

This study investigates the relationship between dose-volume parameters and subjective changes in dyspnea as a measure of RILI and the relationship to spirometry.

Frontiers in Oncology
12/23/2020
Cutaneous Metastasis as the First Presentation of Non-Small-Cell Lung Cancer with a BRAF Mutation

BRAF mutations are emerging therapeutic targets in non-small-cell lung cancer, as they are present in 2–4% of NSCLC cases.

12/23/2020
Predictive Value of Tumor Mutation Burden With Targeted Next-Generation Sequencing in Immunocheckpoint Inhibitors for Non-Small Cell Lung Cancer

To evaluate the clinical predictive value of tumor mutation burden for immune checkpoint inhibitor therapy in patients with non-small cell lung cancer.

01/01/2021
Nogo-B Receptor is Required for Stabilizing TGF-β Type I Receptor and Promotes the TGF-β1-Induced Epithelial-to-Mesenchymal Transition of Non-Small Cell Lung Cancer

Metastasis is the leading cause of death in patients with advanced NSCLC, and epithelial-mesenchymal transition is a crucial event in the metastasis of NSCLC.

01/01/2021
Alpha Thalassemia/Intellectual Disability X-Linked Deficiency Sensitizes Non-Small Cell Lung Cancer to Immune Checkpoint Inhibitors

The immune checkpoint inhibitors have achieved great success in the treatment of NSCLC patients. However, the response rate is low.

Frontiers in Oncology
12/21/2020
Impact of Programmed Death Ligand 1 Expression in Advanced Non-Small–Cell Lung Cancer Patients, Treated by Chemotherapy

This study prospectively assesses the prognostic value of tumor-cell and immune-cell PD-L1 expressions for advanced NSCLC patients.

12/30/2020
Prognostic Implication of Glycolysis Related Gene Signature in Non-Small Cell Lung Cancer

This study is devoted to identify glycolysis related genes as prognostic biomarkers for non-small cell lung cancer. 

01/01/2021
Brain Metastases of Non-Small Cell Lung Cancer: Magnetic Resonance Spectroscopy for Clinical Outcome Assessment in Patients with Stereotactic Radiotherapy

The primary aim of this study is to explore the application of MRS in the assessment of tumor prognosis after stereotactic radiotherapy in NSCLC patients with BM.

12/22/2020
Aberrant Splicing Isoforms Detected by Full-Length Transcriptome Sequencing as Transcripts of Potential Neoantigens in Non-Small Cell Lung Cancer

This study uses a long-read sequencer to construct a comprehensive catalog of aberrant splicing isoforms in non-small-cell lung cancers...

Genome Biology
01/04/2021
Effective Treatment of NSCLC with Surgery After Nivolumab Combined with Chemotherapy

This study reports a case of the patient with resectable non-small cell lung cancer showing a complete response to nivolumab combined with chemotherapy.

12/30/2020
Evolution of Systemic Treatment Uptake and Survival in Advanced Non-Small Cell Lung Cancer

Study findings show systemic treatment rose across three time periods, reflecting the introduction of rapid diagnostic pathways, reflex molecular testing, ICI, and targeted therapies. 

Current Oncology
12/04/2020
Clinically Relevant Prognostic and Predictive Markers for Immune-Checkpoint-Inhibitor Therapy in Non-Small Cell Lung Cancer

Immune checkpoint inhibitors either alone or in combination with chemotherapy have expanded our choice of agents for the palliative treatment of NSCLC patients.

BMC Cancer
12/03/2020
Response Evaluation after Immunotherapy in NSCLC

The present study aims to evaluate the role of early F-18 2-deoxy-2-FDG PET/CT in non-small cell lung cancer patients undergoing immune checkpoint inhibitor treatment.

12/18/2020
Association of Mutation Profiles with Postoperative Survival in Patients with Non–Small Cell Lung Cancer

Study investigators analyze mutations in lung cancer based on the next generation sequencing data of lung tumors surgically removed from the patients, and identified...

Cancers
11/21/2020

source list reference

#7d60d9
#2694a4
#32a887
#85eb24
#352625
#4d4537
#d2093c
#8e3f1c
#76b6c3
#bfcfc8
#c61417
#67e25b
#efef71
#03cffc
#42fc9a
#cc529a
#c59445
#c8cc0c
#bf6be3
#e8085a
#97d1a0
#74e391
#eb6342
#b61f77
#a153ac
#e7f6e3
#6fc969
#9a8c2c
#a9c507
#2b9ab3
#e61923
#990677
#4a7bab
#89f67c
#49a21d
#2c990a
#d7da81
#575662
#a60538
#49cde9
#c20fce
#d95d39